Aclaris Therapeutics Inc. priced a public offering of 8,645,000 common shares at $10.75 each, hoping to raise $92.9 million in gross proceeds.

The Wayne, Pa.-based biopharmaceutical company expects to close the offering Oct. 22.

Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering with Cantor serving as lead manager and Guggenheim Securities as co-manager.

The underwriters have a 30-day option to buy up to an additional 1,296,750 shares at $10.75 apiece from the company.

Aclaris develops therapies for medical and aesthetic dermatology and immunology in the U.S.